|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C07K 16/18 | (2006.01) | ||
| A61K 31/573 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 17/00 | (2006.01) | ||
| A61P 37/06 | (2006.01) |
| (11) | Number of the document | 4087875 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21701890.2 |
| Date of filing the European patent application | 2021-01-08 | |
| (97) | Date of publication of the European application | 2022-11-16 |
| (45) | Date of publication and mention of the grant of the patent | 2024-08-28 |
| (46) | Date of publication of the claims translation | 2024-10-25 |
| (86) | Number | PCT/EP2021/050275 |
| Date | 2021-01-08 |
| (87) | Number | WO 2021/140202 |
| Date | 2021-07-15 |
| (30) | Number | Date | Country code |
| 202062958543 P | 2020-01-08 | US | |
| 202062960647 P | 2020-01-13 | US |
| (72) |
VERHEESEN, Peter , BE
DUPUY, Patrick , BE
|
| (73) |
Argenx BV ,
Industriepark Zwijnaarde 7, 9052 Gent,
BE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Žmogaus neonatalinių Fc receptorių (FcRn) antagonistai, skirti pūslinių ligų gydymui |
| ANTAGONISTS OF HUMAN NEONATAL FC RECEPTOR (FCRN) FOR TREATING PEMPHIGUS DISORDERS |
| Payment date | Validity (years) | Amount | |
| 2024-12-20 | 5 | 115.00 EUR |
| 2026-01-08 |